Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

chemidex pharma limited - mefenamic acid - film-coated tablet - 500 milligram(s) - fenamates; mefenamic acid

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium cromoglycate, quantity: 5 mg - inhalation, pressurised - excipient ingredients: povidone; macrogol 600; apaflurane - the prophylactic treatment of bronchial asthma, including the prevention of exercise induced bronchospasm.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

biomed aust pty ltd - methadone hydrochloride, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: water for injections; colour - biodone forte is indicated for the detoxification and maintenance treatment of dependence on opioid drugs.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.91 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

northstar healthcare unlimited company - alverine citrate - oral capsule - 120mg

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

devatis limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml; potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage);   - powder for oral suspension - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxicillin 50 mg/ml potassium clavulanate 29.776 mg/ml (1:1 silicon dioxide. equivalent to clavulanic acid 12.5 mg/ml. +5% overage)   excipient: citric acid colloidal silicon dioxide dispersible cellulose mannitol sodium citrate sucralose tutti frutti flavour 051880 ap0551 vanilla xanthan gum - amoxiclav should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. amoxiclav is indicated for the short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. susceptibility to amoxiclav will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with amoxiclav susceptible betalactamase-producing organisms may therefore be treated by amoxiclav.

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

beta healthcare international limited, kenya - turpentine oil, methyl salicylate, capsicum oleoresin, camphor synthetic , ammonia - liniment - each 100ml contains: turpentine oil 25.0ml, methyl salicylate 5.0ml, capsicum oleoresin 0.22g, camphor synthetic 2g and ammonia solution forte 0.12ml

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

dermal laboratories (ireland) limited - aluminium chloride hexahydrate - cutaneous solution - 20 percent weight/volume - antihidrotics

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

s kant healthcare limited, india - sulfamethazine , trimethoprim - tablets - 960 mg

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

abbvie limited - prednisolone acetate - eye drops, suspension - corticosteroids, plain; prednisolone